30 closest matches · ranked by relevance
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
Ebola Virus
Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants
Pneumonia
Primary: Highest Grade of Reactogenicity Events in the Adult Cohort: Vaccination 1 — 11; 12; 22; 1 Participants
Vaccine Hesitancy
Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…
Infectious Disease · Pneumonia, Bacterial · Influenza
Primary: Mean Change in Knowledge and Awareness About Vaccine-Preventable Diseases — 3.5; 4.9; 1.3; 1.8 Scores on a scale — p=0.0081
Pneumococcal Infection
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the Quality of Antibodies After PNEUMOVAX and PREVNAR - Monocyte Module M4.15 — 1; 2; 0; 2…
Rotavirus Infection
Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Rotavirus Infections · Gastroenteritis · Diarrhea
Primary: Matched VE Participants — 26; 22; 16; 1 participants
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Diarrhoea
Primary: Proportion of Immunized Infants Exposed to High Breast Milk Anti-rotavirus Immunoglobulin-A Who Fail to Seroconvert — 0.602 Proportion of exposed infants
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Healthy Participants
Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants
Smallpox
Primary: Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine — 2; 4; 3; 4 Participants
Ebola Virus
Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants
Vaccination
Primary: Immunization Rate — 41.7; 40.1; 50.0 Percentage of immunizations
Cervical Cancer · Precancerous Condition
Primary: Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical…
Breast Cancer · Lung Cancer · Prostate Cancer
Primary: Determine Response Rate of Patients > or = to 65 Yrs Diagnosed — 63; 24 participants
Ebola Virus
Primary: Serious Adverse Events. — 6; 6; 8 Participants — p=0.68
HIV Infection · Rotavirus Infection
Primary: Percentage of Participants Developing New Grade >=3 Adverse Events — 1.6; 4.7; 13.5; 12.8 Percentage of participants — p=0.62
Varicella · Chickenpox Vaccines
Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001
Influenza · Vaccine Hesitancy
Primary: Number of Participants Vaccinated at the End of the Campaign Period — 33357; 854 Participants — p=0.216
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Influenza
Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05
Beta Haemolytic Streptococcal Infection
Primary: The Time to First Vaginal Swab That is Type III GBS Culture Positive, With All Previous Cultures Negative for Type III GBS, Not Just the Immediately Preceding Culture…
Tuberculosis
Primary: New Infection With Mycobacterium Tuberculosis — 19; 18 Participants
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
HIV Infections · Meningitis
Primary: Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses…